Clinical Research Institute of Michigan – Shores Rheumatology
Primary Coordinator: Amelia Paliewicz 586-598-3329 X 201
- Indication: Psoriatic Arthritis
- Enrollment Status: Open
- Protocol: I1F-MC-RHDE
- Drug: tirzepatide/ ixekizumab
- Sponsor: Eli Lilly
- Description: A Phase 4, Prospective, Open-Label, Single-Arm Study to Assess the Effectiveness of Tirzepatide after Initiation of Ixekizumab in Adult Participants with Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice
Clinical Research Institute of Michigan – Shores Rheumatology
Primary Coordinator: Amelia Paliewicz 586-598-3329 X 201
- Indication: Rheumatoid Arthritis
- Enrollment Status: Open
- Protocol: IMVT-1402-2601
- Drug: IMVT-1402
- Sponsor: Immunovant
- Description: A Phase 2b, Multicenter, Double-blind, Placebo-controlled Randomized Withdrawal Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 in Adult Participants with Active, Difficult-to-treat, ACPA-Positive Rheumatoid Arthritis
Clinical Research Institute of Michigan – Shores Rheumatology
Primary Coordinator: Amelia Paliewicz 586-598-3329 X 201
- Indication: Rheumatoid Arthritis
- Enrollment Status: Closed
- Protocol: PRIMA-102 “Aqtual”
- Drug: N/A: Collection for Assessment of DMARD Initiation
- Sponsor: Aqtual
- Description: Prospective, Multi-Center, Observational, Whole Blood Specimen Collection Study in Participants with Rheumatoid Arthritis with inadequate response or intolerance to a DMARD Starting a New bDMARD or tsDMARD Treatment +/- csDMARD
Clinical Research Institute of Michigan – Shores Rheumatology
Primary Coordinator: Amelia Paliewicz 586-598-3329 X 201
- Indication: Rheumatoid Arthritis
- Enrollment Status: Closed
- Protocol: GS-US-417-0304
- Drug: Filgotinib
- Sponsor: Gilead
- Description: A Multicenter, Open-Label, Long-Term Extension Study to Assess the Safety and Efficacy of Filgotinib in Subjects with Rheumatoid Arthritis
Clinical Research Institute of Michigan – Shores Rheumatology
Primary Coordinator: Amelia Paliewicz 586-598-3329 X 201
- Indication: Sjogren’s Syndrome
- Enrollment Status: Open
- Protocol: HZNP-DAZ-301, HZNP-DAZ-301 HZNP-DAZ-304 “Oasis”
- Drug: Dazodalibep
- Sponsor: Horizon/Amgen
- Description:
- 301 Description: A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren’s Syndrome With Moderate-to-severe Systemic Disease Activity
- 303 Description: A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren’s Syndrome With Moderate-to-Severe Symptom State
- 304 Description: A Multicenter, Long term, Randomized, Extension Study to Evaluate Safety and Tolerability of Dazodalibep in Subjects with Sjögren’s Syndrome (SS)